Congenital toxoplasma gondii infection

Marmara Medical Journal

Volumn 21, Issue 1, 2008, Pages 89-101

  Dalgiç, Nazan ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

Congenital infection; Diagnosis; Follow up; Toxoplasma gondii; Treatment

Indexed keywords

FOLINIC ACID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; PYRIMETHAMINE SULFADIAZINE; SPIRAMYCIN; TOXOPLASMA GONDII VACCINE;

DISEASE TRANSMISSION; FOLLOW UP; FOOD CONTAMINATION; HISTOPATHOLOGY; HUMAN; INCIDENCE; PARASITE ISOLATION; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREGNANT WOMAN; PREVALENCE; REVIEW; SEROLOGY; TOXOPLASMA GONDII; TOXOPLASMOSIS;

EID: 43449126838     PISSN: 10191941     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Rorman E, Zamir CS, Rilkis I, Ben-David H. Congenital toxoplasmosis - prenatal aspects of Toxoplasma gondii infection. Reprod Toxicol 2006; 21: 458-472.
2. Remington JS, McLeod R, Thulliez P, Desmonts G. Toxoplasmosis. In: Remington SS, Klein JO, Wilson CB, Baker CJ, eds. Infectious Diseases of the Fetus and Newborn Infant. 6th ed. Philadelphia, PA, IL: Elsevier Saunders; 2006: 947-1091.
3. Kravetz JD, Federman DG. Toxoplasmosis in pregnancy. Am J Med 2005; 118: 212-216.
4. Suzuki Y, Wong SY, Grumet FC, et al. Evidence for genetic regulation of susceptibility to toxoplasmic encephalitis in AIDS patients. J Infect Dis 1996; 173: 265-268.
5. Mack DG, Johnson JJ, Roberts F, Roberts CW, Estes RG, David C, et al. HLA-class II genes modify outcome of Toxoplasma gondii infection. Int J Parasitol 1999; 29: 1351-1358.
6. Fatoohi AF, Cozon GJ, Wallon M, Kahi S, Gay-Andrieu F, Greenland T, et al. Cellular immunity to Toxoplasma gondii in congenitally infected newborns and immunocompetent infected hosts. Eur J Clin Microbiol Infect Dis 2003; 22: 181-184.
7. Montoya JG, Liesenfeld O. Toxoplasmosis in pregnancy. Lancet 2004;363:1965-1976.
8. Lekutis C, Ferguson DJ, Boothroyd JC. Toxoplasma gondii: identification of a developmentally regulated family of genes related to SAG2. Exp Parasitol 2000;96:89-96.
9. Sibley LD. Intracellular parasite invasion strategies. Science 2004;304(5668):248-253.
10. Kissinger JC, Gajria B, Li L, Paulsen IT, Roos DS. ToxoDB: accessing the Toxoplasma gondii genome. Nucleic Acids Res 2003; 31: 234-236.
11. Chardes T, Buzoni-Gatel D, Lepage A, Bernard F, Bout D. Toxoplasma gondii oral infection induces specific cytotoxic CD8 alpha/beta+ Thy-1+ gut intraepithelial lymphocytes, lytic for parasite-infected enterocytes. J Immunol 1994; 153: 4596-4603
12. Mineo JR, McLeod R, Mack D, Smith J, Khan IA, Ely KH, et al. Antibodies to Toxoplasma gondii major surface protein (SAG-1, P30) inhibit infection of host cells and are produced in murine intestine after peroral infection. J Immunol 1993; 150: 3951-3964.
13. Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol 2000; 30: 1217-58.
14. Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB. Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol 2001; 154: 357-365.
15. Aslan G, Altintaş K, Seyrek A, Kültür N, Güngör Ç. Şanliurfa bölgesindeki kadinlarda Sabin-Feldman testi ile toksoplazma gondii prevalansinin saptanmasi. Erciyes Tip Dergisi 1998;20:149-153.
16. Güngör Ç, Özsan M, Karaarslan M. Hamileleerde toksoplasma total, IgM ve Ig6 antikor seropozitifliǧinin araştirilmasi. Ankara Üniversitesi Tip Fakültesi Mecmuasi 2000; 53:91-93.
17. Kapperud G, Jenum PA, Stray-Pedersen B, Melby KK, Eskild A, Eng J. Risk factors for Toxoplasma gondii infection in pregnancy. Results of a prospective case-control study in Norway. Am J Epidemiol 1996; 144: 405-412.
18. Buffolano W, Gilbert RE, Holland FJ, Fratta D, Palumbo F, Ades AE. Risk factors for recent toxoplasma infection in pregnant women in Naples. Epidemiol Infect 1996; 116: 347-351.
19. Bobic B, Jevremovic I, Marinkovic J, Sibalic D, Djurkovic-Djakovic O. Risk factors for Toxoplasma infection in a reproductive age female population in the area of Belgrade, Yugoslavia. Eur J Epidemiol 1998; 14: 605-610.
20. Cook AJ, Gilbert RE, Buffolano W, Zufferey J, Petersen E, Jenum PA, et al. Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European Research Network on Congenital Toxoplasmosis. Bmj 2000; 321: 142-147.
21. Boyer KM, Holfels E, Roizen N, Swisher C, Mack D, Remington J, et al. Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: Implications for prenatal management and screening. Am J Obstet Gynecol 2005; 192: 564-571.
22. Toker A, İplikçi MT, Ersöz M, Eriş FN.Hamile kadinlarda toksoplazma antikorlarina rastlama sikliǧi ve beslenme ile ilişkisi. Türkiye Parazitoloji Dergisi 1994,18:277-285.
23. Jones J, Lopez A, Wilson M. Congenital toxoplasmosis. Am Fam Physician 2003; 67: 2131-2138.
24. Dubey JP. Toxoplasmosis. J Am Vet Med Assoc 1994; 205: 1593-1598.
25. Antsaklis A, Daskalakis G, Papantoniou N, Mentis A, Michalas S. Prenatal diagnosis of congenital toxoplasmosis. Prenat Diagn 2002; 22: 1107-1111.
26. Dollfus H, Dureau P, Hennequin C, Uteza Y, Bron A, Dufier JL. Congenital toxoplasma chorioretinitis transmitted by preconceptionally immune women. Br J Ophthalmol 1998; 82: 1444-1445.
27. Chemla C, Villena I, Aubert D, Hornoy P, Dupouy D, Leroux B, et al. Preconception seroconversion and maternal seronegativity at delivery do not rule out the risk of congenital toxoplasmosis. Clin Diagn Lab Immunol 2002; 9: 489-490.
28. Silveira C, Ferreira R, Muccioli C, Nussenblatt R, Belfort R, Jr. Toxoplasmosis transmitted to a newborn from the mother infected 20 years earlier. Am J Ophthalmol 2003; 136: 370-371.
29. Lebech M, Joynson DH, Seitz HM, Thulliez P, Gilbert RE, Dutton GN, et al. Classification system and case definitions of Toxoplasma gondii infection in immunocompetent pregnant women and their congenitally infected offspring. European Research Network on Congenital Toxoplasmosis. Eur J Clin Microbiol Infect Dis 1996; 15: 799-805.
30. Lappalainen M, Hedman K. Serodiagnosis of toxoplasmosis. The impact of measurement of IgG avidity. Ann Ist Super Sanita 2004; 40: 81-88.
31. Gay-Andrieu F, Marty P, Pialat J, Sournies G, Drier de Laforte T, Peyron F. Fetal toxoplasmosis and negative amniocentesis: necessity of an ultrasound follow-up. Prenat Diagn 2003; 23: 558-560.
32. McAuley J, Boyer KM, Patel D, Mets M, Swisher C, Roizen N, et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis 1994; 18: 38-72.
33. Swisher CN, Boyer K, McLeod R. Congenital toxoplasmosis. The Toxoplasmosis Study Group. Semin Pediatr Neurol 1994; 1: 4-25.
34. Gras L, Wallon M, Pollak A, et al. Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. Acta Paediatr 2005; 94: 1721-1731.
35. Vutova K, Peicheva Z, Popova A, Markova V, Mincheva N, Todorov T. Congenital toxoplasmosis: eye manifestations in infants and children. Ann Trop Paediatr 2002; 22: 213-218.
36. Potasman I, Davidovitch M, Tal Y, Tal J, Zelnik N, Jaffe M. Congenital toxoplasmosis: a significant cause of neurological morbidity in Israel? Clin Infect Dis 1995; 20: 259-262.
37. Montoya JG. Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis. J Infect Dis 2002; 185 Suppl 1: S73-82.
38. Hedman K, Lappalainen M, Seppaia I, Makela O. Recent primary toxoplasma infection indicated by a low avidity of specific IgG. J Infect Dis 1989; 159: 736-740.
39. Montoya JG, Liesenfeld O, Kinney S, Press C, Remington JS. VIDAS test for avidity of Toxoplasma-specific immunoglobulin G for confirmatory testing of pregnant women. J Clin Microbiol 2002; 40: 2504-2508.
40. Jenum PA, Stray-Pedersen B, Gundersen AG. Improved diagnosis of primary Toxoplasma gondii infection in early pregnancy by determination of antitoxoplasma immunoglobulin G avidity. J Clin Microbiol 1997; 35: 1972-1977.
41. Lappalainen M, Koskela P, Koskiniemi M, et al. Toxoplasmosis acquired during pregnancy: improved serodiagnosis based on avidity of IgG. J Infect Dis 1993; 167: 691-697.
42. Dannemann BR, Vaughan WC, Thulliez P, Remington JS. Differential agglutination test for diagnosis of recently acquired infection with Toxoplasma gondii. J Clin Microbiol 1990; 28: 1928-1933.
43. Liesenfeld O, Press C, Montoya JG, et al. False-positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM test. J Clin Microbiol 1997; 35: 174-178.
44. Bobic B, Sibalic D, Djurkovic-Djakovic O. High levels of IgM antibodies specific for Toxoplasma gondii in pregnancy 12 years after primary toxoplasma infection. Case report. Gynecol Obstet Invest 1991; 31: 182-184.
45. Wilson M, Remington JS, Clavet C, Varney G, Press C, Ware D. Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. The FDA Toxoplasmosis Ad Hoc Working Group. J Clin Microbiol 1997; 35: 3112-3115.
46. Hohlfeld P, Daffos F, Costa JM, Thulliez P, Forestier F, Vidaud M. Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid. N Engl J Med 1994; 331: 695-699.
47. Romand S, Wallon M, Franck J, Thulliez P, Peyron F, Dumon H. Prenatal diagnosis using polymerase chain reaction on amniotic fluid for congenital toxoplasmosis. Obstet Gynecol 2001; 97: 296-300.
48. Bastien P. Molecular diagnosis of toxoplasmosis. Trans R Soc Trop Med Hyg 2002; 96 Suppl 1: S205-S215.
49. Remington JS, Thulliez P, Montoya JG. Recent developments for diagnosis of toxoplasmosis. J Clin Microbiol 2004; 42: 941-945.
50. Pratlong F, Boulot P, Villena I, Issert E, Tamby I, Cazenave J, et al. Antenatal diagnosis of congenital toxoplasmosis: evaluation of the biological parameters in a cohort of 286 patients. Br J Obstet Gynaecol 1996; 103: 552-557.
51. Fricker-Hidalgo H, Pelloux H, Muet F, Racinet C, Bost M, Goullier-Fleuret A, et al. Prenatal diagnosis of congenital toxoplasmosis: comparative value of fetal blood and amniotic fluid using serological techniques and cultures. Prenat Diagn 1997; 17: 831-835.
52. Hezard N, Marx-Chemla C, Foudrinier F, et al. Prenatal diagnosis of congenital toxoplasmosis in 261 pregnancies. Prenat Diagn 1997; 17: 1047-1054.
53. Holliman RE, Johnson JD, Constantine G, Bissenden JG, Nicolaides K, Savva D. Difficulties in the diagnosis of congenital toxoplasmosis by cordocentesis. Case report. Br J Obstet Gynaecol 1991; 98: 832-834.
54. Stepick-Biek P, Thulliez P, Araujo FG, Remington JS. IgA antibodies for diagnosis of acute congenital and acquired toxoplasmosis. J Infect Dis 1990; 162: 270-273.
55. Krahenbuhl JL, Gaines JD, Remington JS. Lymphocyte transformation in human toxoplasmosis. J Infect Dis 1972; 125: 283-288.
56. Wilson CB, Desmonts G, Couvreur J, Remington JS. Lymphocyte transformation in the diagnosis of congenital toxoplasma infection. N Engl J Med 1980; 302: 785-788.
57. McLeod R, Mack DG, Boyer K, Mets M, Roizen N, Swisher C, et al. Phenotypes and functions of lymphocytes in congenital toxoplasmosis. J Lab Clin Med 1990; 116: 623-635.
58. Foulon W, Villena I, Stray-Pedersen B, et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol 1999; 180: 410-415.
59. Gras L, Gilbert RE, Ades AE, Dunn DT. Effect of prenatal treatment on the risk of intracranial and ocular lesions in children with congenital toxoplasmosis. Int J Epidemiol 2001; 30: 1309-1313.
60. Gilbert R, Dunn D, Wallon M, Hayde M, Prusa A, Lebech M, et al. Ecological comparison of the risks of mother-to-child transmission and clinical manifestations of congenital toxoplasmosis according to prenatal treatment protocol. Epidemiol Infect 2001; 127: 113-120.
61. Luder CG, Giraldo-Velasquez M, Sendtner M, Gross U. Toxoplasma gondii in primary rat CNS cells: differential contribution of neurons, astrocytes, and microglial cells for the intracerebral development and stage differentiation. Exp Parasitol 1999; 93: 23-32.
62. Gilbert R, Gras L. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. Bjog 2003; 110: 112-120.
63. Ricci M, Pentimalli H, Thaller R, Rava L, Di Ciommo V. Screening and prevention of congenital toxoplasmosis: an effectiveness study in a population with a high infection rate. J Matern Fetal Neonatal Med 2003; 14: 398-403.
64. Szenasi Z, Ozsvar Z, Nagy E, Jeszenszky M, Szabo J, Gellen J, et al. Prevention of congenital toxoplasmosis in Szeged, Hungary. Int J Epidemiol 1997; 26: 428-435.
65. Wilson CB, Remington JS. What can be done to prevent congenital toxoplasmosis? Am J Obstet Gynecol 1980 ;138:357-363.
66. Foulon W, Naessens A, Ho-Yen D. Prevention of congenital toxoplasmosis. J Pernat Med 2000;28:337-345.
67. Çetin N, Elmas B, Büyükpatir F, Güneş T. Yenidoǧanlarda toksoplazma antikor prevalansi ve konjenital toksoplazma enfeksiyonu sikliǧi. Erciyes Tip Dergisi 2000;22:141-149.
68. ACOG practice bulletin. Perinatal viral and parasitic infections. Number 20, September 2000. (Replaces educational bulletin number 177, February 1993). American College of Obstetrics and Gynecologists. Int J Gynaecol Obstet 2002; 76: 95-107.
69. Thulliez P. Screening programme for congenital toxoplasmosis in France. Scand J Infect Dis Suppl 1992; 84: 43-45.
70. Aspock H, Pollak A. Prevention of prenatal toxoplasmosis by serological screening of pregnant women in Austria. Scand J Infect Dis Suppl 1992; 84: 32-7.
71. Lopez A, Dietz VJ, Wilson M, Navin TR, Jones JL. Preventing congenital toxoplasmosis. MMWR Recomm Rep 2000; 49: 59-68.
72. Hsu HW, Grady GF, Maguire JH, Weiblen BJ, Hoff R. Newborn screening for congenital Toxoplasma infection: five years experience in Massachusetts, USA. Scand J Infect Dis Suppl 1992; 84: 59-64.
73. Neto EC, Rubin R, Schulte J, Giugliani R. Newborn screening for congenital infectious diseases. Emerg Infect Dis 2004; 10: 1068-1073.
74. Buxton D, Innes EA. A commercial vaccine for ovine toxoplasmosis. Parasitology 1995; 110 Suppl: S11-S16.
75. Bulow R, Boothroyd JC. Protection of mice from fatal Toxoplasma gondii infection by immunization with p30 antigen in liposomes. J Immunol 1991; 147: 3496-3500.
76. Petersen E, Nielsen HV, Christiansen L, Spenter J. Immunization with E. coli produced recombinant T. gondii SAG1 with alum as adjuvant protect mice against lethal infection with Toxoplasma gondii. Vaccine 1998; 16: 1283-1289.
77. Ismael AB, Sekkai D, Collin C, Bout D, Mevelec MN. The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis. Infect Immun 2003; 71: 6222-8.
78. Wallon M, Kodjikian L, Binquet C, Garweg J, Fleury J, Quantin C, et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics 2004; 113: 1567-1572.